MannKind rallies on Afrezza optimism

|About: MannKind Corporation (MNKD)|By:, SA News Editor

Shares of MannKind (MNKD +5%) are strong to start the week.

SA contributor Maredin Capital Advisors — who has "owned shares for the better part of six years and endured quite a bit of volatility in the process" — likens Afrezza's market potential to Lipitor and Plavix and says FDA approval is "a low hurdle at this juncture."

The author goes on to say that Afrezza "will likely become the dominant player in the $44B insulin market due to its unique pharmacokinetics/efficacy and convenience." The article appeared elsewhere last month.

Also bullish is SA contributor Stock Whisper, who highlights the company's presentation at the Piper Jaffray healthcare conference.